Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.60 |
| ▸ | PLK1 | P53350 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517750 | 1.00 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL29364229 | 0.87 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL310477 | 0.87 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL30497489 | 0.86 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL518445 | 0.86 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL520828 | 0.84 | ALDH1A1 (0.68) | ALDH1A1LMNAMAPTSIRT6HTR6 | |
| SCHEMBL25261530 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL12312063 | 0.83 | ALDH1A1 (0.63) | ALDH1A1LMNAMAPTSIRT6PLK1 | |
| SCHEMBL311272 | 0.82 | ALDH1A1 (0.73) | ALDH1A1LMNAMAPTSIRT6HTR6 | |
| SCHEMBL21847022 | 0.81 | LGMN (0.42) | ALDH1A1MAPTPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | ALDH1A1 214/4885LMNA 1889/4885MAPT 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.